Physician profile

George B Cavanagh

Family Medicine · Bowie, MD

NPI 1477554293

$2,429.11

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $320.18 2019-2022
Astellas Pharma US INC $305.16 2019
Novo Nordisk INC $236.67 2019-2022
Merck Sharp & Dohme LLC $187.75 2019-2020
Glaxosmithkline, LLC. $173.52 2019-2022
Pfizer INC. $147.26 2019-2020
Amgen INC. $124.38 2019
Abbvie INC. $122.20 2022
Kowa Pharmaceuticals America, INC. $118.84 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $106.43 2019
Amarin Pharma, INC. $103.71 2019-2020
Lilly USA, LLC $95.32 2019-2022
E.R. Squibb & Sons, L.L.C. $59.21 2019-2022
Takeda Pharmaceuticals U.S.A., INC. $50.11 2019-2020
Allergan, INC. $49.34 2019-2020
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $49.15 2019-2022
Novartis Pharmaceuticals Corporation $38.48 2019-2020
Boston Scientific Corporation $35.34 2019-2022
Biohaven Pharmaceutical Holding Company LTD. $22.66 2022
Abbott Laboratories $20.45 2022
Sanofi Pasteur INC. $18.36 2020
Shire North American Group INC $17.11 2019
Medtronic Vascular, INC. $14.98 2019
Eisai INC. $12.50 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George B Cavanagh

$2,429.11

in general payments reported 2019-2025

Years
2019-2022
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/21568/george-b-cavanagh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.